Dianthus Therapeutics (DNTH) CFO Ryan Savitz sold 8,224 shares of common stock for approximately $739,000, as disclosed in an SEC Form 4 filing. This transaction, executed under a Rule 10b5-1 plan, involved the exercise of stock options, converting them into shares that were immediately sold. Following this sale, Savitz holds no direct shares but retains beneficial ownership through 71,776 unexercised stock options.
This sale comes on the heels of a significant stock rally, driven by positive interim results from a phase 3 trial of the company’s lead candidate, claseprubart. The stock surged after the trial demonstrated a 50% response rate with fewer participants than planned, prompting a $719 million upsized secondary offering in March. Savitz’s sale appears more aligned with routine liquidity management rather than a signal of distress, as he maintains a substantial position in stock options.
For investors, the key takeaway is that while Savitz’s direct ownership has diminished, his continued stake in the form of options indicates confidence in the company’s future, especially following its recent clinical successes and strong institutional backing.
Source: fool.com